MENY

Gällande vårdprogram akut myeloisk leukemi (AML)

Fastställt av Regionala cancercentrum i samverkan 2019-04-29

24. Referenser

1. Juliusson G, Lazarevic V, Hörsted A-S. Akut myeloisk leukemi (AML). Kvalitetsrapport från Nationella AML-registret för diagnosår 1997-2014: RCC i samverkan;  [updated 2016].

2. Stein EM, Tallman MS. Emerging therapeutic drugs for AML. Blood. 2016;127(1):71-8.

3. Wei AH, Tiong IS. Midostaurin, enasidenib, CPX-351, gemtuzumab ozogamicin, and venetoclax bring new hope to AML. Blood. 2017;130(23):2469-74.

4. Juliusson G, Antunovic P, Derolf A, Lehmann S, Mollgard L, Stockelberg D, et al. Age and acute myeloid leukemia: real world data on decision to treat and outcomes from the Swedish Acute Leukemia Registry. Blood. 2009;113(18):4179-87.

5. Wahlin A, Billstrom R, Bjor O, Ahlgren T, Hedenus M, Hoglund M, et al. Results of risk-adapted therapy in acute myeloid leukaemia. A long-term population-based follow-up study. European journal of haematology. 2009;83(2):99-107.

6. Juliusson G, Karlsson K, Lazarevic V, Wahlin A, Brune M, Antunovic P, et al. Hematopoietic stem cell transplantation rates and long-term survival in acute myeloid and lymphoblastic leukemia: real-world population-based data from the Swedish Acute Leukemia Registry 1997-2006. Cancer. 2011;117(18):4238-46.

7. Juliusson, G. (2016). Nationellt register för akut myeloisk leukemi hos vuxna. . R. C. i. Samverkan. www.cancercentrum.se. Rapport nr 9.

8. Dohner H, Estey E, Grimwade D, Amadori S, Appelbaum FR, Buchner T, et al. Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel. Blood. 2017;129(4):424-47.

9. Derolf AR, Kristinsson SY, Andersson TM, Landgren O, Dickman PW, Bjorkholm M. Improved patient survival for acute myeloid leukemia: a population-based study of 9729 patients diagnosed in Sweden between 1973 and 2005. Blood. 2009;113(16):3666-72.

10. Guyatt G, Oxman AD, Akl EA, Kunz R, Vist G, Brozek J, et al. GRADE guidelines: 1. Introduction-GRADE evidence profiles and summary of findings tables. Journal of clinical epidemiology. 2011;64(4):383-94.

11. Juliusson G, Abrahamsson J, Lazarevic V, Antunovic P, Derolf A, Garelius H, et al. Prevalence and characteristics of survivors from acute myeloid leukemia in Sweden. Leukemia. 2017;31(3):728-31.

12. Granfeldt Ostgard LS, Medeiros BC, Sengelov H, Norgaard M, Andersen MK, Dufva IH, et al. Epidemiology and Clinical Significance of Secondary and Therapy-Related Acute Myeloid Leukemia: A National Population-Based Cohort Study. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2015;33(31):3641-9.

13. Hulegardh E, Nilsson C, Lazarevic V, Garelius H, Antunovic P, Rangert Derolf A, et al. Characterization and prognostic features of secondary acute myeloid leukemia in a population-based setting: a report from the Swedish Acute Leukemia Registry. Am J Hematol. 2015;90(3):208-14.

14. Pedersen-Bjergaard J, Andersen MK, Andersen MT, Christiansen DH. Genetics of therapy-related myelodysplasia and acute myeloid leukemia. Leukemia. 2008;22(2):240-8.

15. Godley LA. Inherited predisposition to acute myeloid leukemia. Semin Hematol. 2014;51(4):306-21.

16. Furutani E, Shimamura A. Germline Genetic Predisposition to Hematologic Malignancy. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2017;35(9):1018-28.

17. Network CGA. Genomic and Epigenomic Landscapes of Adult De Novo Acute Myeloid Leukemia. New England Journal of Medicine. 2013;368(22):2059-74.

18. Grimwade D, Ivey A, Huntly BJ. Molecular landscape of acute myeloid leukemia in younger adults and its clinical relevance. Blood. 2016;127(1):29-41.

19. Metzeler KH, Herold T, Rothenberg-Thurley M, Amler S, Sauerland MC, Gorlich D, et al. Spectrum and prognostic relevance of driver gene mutations in acute myeloid leukemia. Blood. 2016;128(5):686-98.

20. Papaemmanuil E, Gerstung M, Bullinger L, Gaidzik VI, Paschka P, Roberts ND, et al. Genomic Classification and Prognosis in Acute Myeloid Leukemia. The New England journal of medicine. 2016;374(23):2209-21.

21. Eriksson A, Lennartsson A, Lehmann S. Epigenetic aberrations in acute myeloid leukemia: Early key events during leukemogenesis. Exp Hematol. 2015;43(8):609-24.

22. Becker H, Marcucci G, Maharry K, Radmacher MD, Mrozek K, Margeson D, et al. Favorable prognostic impact of NPM1 mutations in older patients with cytogenetically normal de novo acute myeloid leukemia and associated gene- and microRNA-expression signatures: a Cancer and Leukemia Group B study. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2010;28(4):596-604.

23. Bene MC, Nebe T, Bettelheim P, Buldini B, Bumbea H, Kern W, et al. Immunophenotyping of acute leukemia and lymphoproliferative disorders: a consensus proposal of the European LeukemiaNet Work Package 10. Leukemia. 2011;25(4):567-74.

24. Richards S, Aziz N, Bale S, Bick D, Das S, Gastier-Foster J, et al. Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology. Genet Med. 2015;17(5):405-24.

25. Arber DA, Orazi A, Hasserjian R, Thiele J, Borowitz MJ, Le Beau MM, et al. The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood. 2016;127(20):2391-405.

26. Vardiman JW, Thiele J, Arber DA, Brunning RD, Borowitz MJ, Porwit A, et al. The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes. Blood. 2009;114(5):937-51.

27. Nacheva EP, Grace CD, Brazma D, Gancheva K, Howard-Reeves J, Rai L, et al. Does BCR/ABL1 positive acute myeloid leukaemia exist? British journal of haematology. 2013;161(4):541-50.

28. Neuendorff NR, Hemmati P, Arnold R, Ihlow J, Dorken B, Muller-Tidow C, et al. BCR-ABL(+) acute myeloid leukemia: are we always dealing with a high-risk disease? Blood Adv. 2018;2(12):1409-11.

29. Mendler JH, Maharry K, Radmacher MD, Mrozek K, Becker H, Metzeler KH, et al. RUNX1 mutations are associated with poor outcome in younger and older patients with cytogenetically normal acute myeloid leukemia and with distinct gene and MicroRNA expression signatures. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2012;30(25):3109-18.

30. Delavigne K, Berard E, Bertoli S, Corre J, Duchayne E, Demur C, et al. Hemophagocytic syndrome in acute myeloid leukemia patients undergoing intensive chemotherapy. Haematologica. 2013.

31. Cheson BD, Bennett JM, Kopecky KJ, Buchner T, Willman CL, Estey EH, et al. Revised recommendations of the International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid Leukemia. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2003;21(24):4642-9.

32. Dohner H, Weisdorf DJ, Bloomfield CD. Acute Myeloid Leukemia. The New England journal of medicine. 2015;373(12):1136-52.

33. Grimwade D, Hills RK, Moorman AV, Walker H, Chatters S, Goldstone AH, et al. Refinement of cytogenetic classification in acute myeloid leukemia: determination of prognostic significance of rare recurring chromosomal abnormalities among 5876 younger adult patients treated in the United Kingdom Medical Research Council trials. Blood. 2010;116(3):354-65.

34. Patel JP, Gönen M, Figueroa ME, Fernandez H, Sun Z, Racevskis J, et al. Prognostic Relevance of Integrated Genetic Profiling in Acute Myeloid Leukemia. New England Journal of Medicine. 2012;366(12):1079-89.

35. Lindsley RC, Mar BG, Mazzola E, Grauman PV, Shareef S, Allen SL, et al. Acute myeloid leukemia ontogeny is defined by distinct somatic mutations. Blood. 2015;125(9):1367-76.

36. Duployez N, Marceau-Renaut A, Boissel N, Petit A, Bucci M, Geffroy S, et al. Comprehensive mutational profiling of core binding factor acute myeloid leukemia. Blood. 2016;127(20):2451-9.

37. Dochez V, Corre P, Riteau AS, Le Vaillant C. [Correlation between antenatal ultrasound and postnatal diagnosis in cleft lip or palate: A retrospective study of 44 cases]. Gynecol Obstet Fertil. 2015;43(12):767-72.

38. Schlenk RF, Kayser S, Bullinger L, Kobbe G, Casper J, Ringhoffer M, et al. Differential impact of allelic ratio and insertion site in FLT3-ITD-positive AML with respect to allogeneic transplantation. Blood. 2014;124(23):3441-9.

39. Straube J, Ling VY, Hill GR, Lane SW. The impact of age, NPM1(mut), and FLT3(ITD) allelic ratio in patients with acute myeloid leukemia. Blood. 2018;131(10):1148-53.

40. Bakst RL, Tallman MS, Douer D, Yahalom J. How I treat extramedullary acute myeloid leukemia. Blood. 2011;118(14):3785-93.

41. Lazarevic V, Horstedt AS, Johansson B, Antunovic P, Billstrom R, Derolf A, et al. Incidence and prognostic significance of karyotypic subgroups in older patients with acute myeloid leukemia: the Swedish population-based experience. Blood cancer journal. 2014;4:e188.

42. Leith CP, Kopecky KJ, Godwin J, McConnell T, Slovak ML, Chen IM, et al. Acute myeloid leukemia in the elderly: assessment of multidrug resistance (MDR1) and cytogenetics distinguishes biologic subgroups with remarkably distinct responses to standard chemotherapy. A Southwest Oncology Group study. Blood. 1997;89(9):3323-9.

43. Sorror ML, Sandmaier BM, Storer BE, Maris MB, Baron F, Maloney DG, et al. Comorbidity and disease status based risk stratification of outcomes among patients with acute myeloid leukemia or myelodysplasia receiving allogeneic hematopoietic cell transplantation. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2007;25(27):4246-54.

44. Bertoli S, Bories P, Bene MC, Daliphard S, Lioure B, Pigneux A, et al. Prognostic impact of day 15 blast clearance in risk-adapted remission induction chemotherapy for younger patients with acute myeloid leukemia: long-term results of the multicenter prospective LAM-2001 trial by the GOELAMS study group. Haematologica. 2014;99(1):46-53.

45. Rowe JM, Kim HT, Cassileth PA, Lazarus HM, Litzow MR, Wiernik PH, et al. Adult patients with acute myeloid leukemia who achieve complete remission after 1 or 2 cycles of induction have a similar prognosis: a report on 1980 patients registered to 6 studies conducted by the Eastern Cooperative Oncology Group. Cancer. 2010;116(21):5012-21.

46. Wheatley K, Burnett AK, Goldstone AH, Gray RG, Hann IM, Harrison CJ, et al. A simple, robust, validated and highly predictive index for the determination of risk-directed therapy in acute myeloid leukaemia derived from the MRC AML 10 trial. United Kingdom Medical Research Council's Adult and Childhood Leukaemia Working Parties. British journal of haematology. 1999;107(1):69-79.

47. Perea G, Lasa A, Aventin A, Domingo A, Villamor N, Queipo de Llano MP, et al. Prognostic value of minimal residual disease (MRD) in acute myeloid leukemia (AML) with favorable cytogenetics [t(8;21) and inv(16)]. Leukemia. 2006;20(1):87-94.

48. Cornelissen JJ, Blaise D. Hematopoietic stem cell transplantation for patients with AML in first complete remission. Blood. 2016;127(1):62-70.

49. Vidriales MB, Perez-Lopez E, Pegenaute C, Castellanos M, Perez JJ, Chandia M, et al. Minimal residual disease evaluation by flow cytometry is a complementary tool to cytogenetics for treatment decisions in acute myeloid leukaemia. Leukemia research. 2016;40:1-9.

50. Doubek M, Palasek I, Pospisil Z, Borsky M, Klabusay M, Brychtova Y, et al. Detection and treatment of molecular relapse in acute myeloid leukemia with RUNX1 (AML1), CBFB, or MLL gene translocations: frequent quantitative monitoring of molecular markers in different compartments and correlation with WT1 gene expression. Exp Hematol. 2009;37(6):659-72.

51. Ommen HB, Hokland P, Haferlach T, Abildgaard L, Alpermann T, Haferlach C, et al. Relapse kinetics in acute myeloid leukaemias with MLL translocations or partial tandem duplications within the MLL gene. British journal of haematology. 2014;165(5):618-28.

52. Lane S, Saal R, Mollee P, Jones M, Grigg A, Taylor K, et al. A >or=1 log rise in RQ-PCR transcript levels defines molecular relapse in core binding factor acute myeloid leukemia and predicts subsequent morphologic relapse. Leuk Lymphoma. 2008;49(3):517-23.

53. Zhu HH, Zhang XH, Qin YZ, Liu DH, Jiang H, Chen H, et al. MRD-directed risk stratification treatment may improve outcomes of t(8;21) AML in the first complete remission: results from the AML05 multicenter trial. Blood. 2013;121(20):4056-62.

54. Walter RB, Gooley TA, Wood BL, Milano F, Fang M, Sorror ML, et al. Impact of pretransplantation minimal residual disease, as detected by multiparametric flow cytometry, on outcome of myeloablative hematopoietic cell transplantation for acute myeloid leukemia. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2011;29(9):1190-7.

55. Buccisano F, Maurillo L, Piciocchi A, Del Principe MI, Picardi A, Cerretti R, et al. Pre-transplant persistence of minimal residual disease does not contraindicate allogeneic stem cell transplantation for adult patients with acute myeloid leukemia. Bone marrow transplantation. 2017;52(3):473-5.

56. Schuurhuis GJ, Heuser M, Freeman S, Bene MC, Buccisano F, Cloos J, et al. Minimal/measurable residual disease in AML: a consensus document from the European LeukemiaNet MRD Working Party. Blood. 2018;131(12):1275-91.

57. Ofran Y, Rowe JM. Introducing minimal residual disease in acute myeloid leukemia. Curr Opin Hematol. 2015;22(2):139-45.

58. Kayser S, Walter RB, Stock W, Schlenk RF. Minimal residual disease in acute myeloid leukemia--current status and future perspectives. Curr Hematol Malig Rep. 2015;10(2):132-44.

59. Cruz NM, Mencia-Trinchant N, Hassane DC, Guzman ML. Minimal residual disease in acute myelogenous leukemia. Int J Lab Hematol. 2017;39 Suppl 1:53-60.

60. Ivey A, Hills RK, Simpson MA, Jovanovic JV, Gilkes A, Grech A, et al. Assessment of Minimal Residual Disease in Standard-Risk AML. The New England journal of medicine. 2016;374(5):422-33.

61. Kronke J, Schlenk RF, Jensen KO, Tschurtz F, Corbacioglu A, Gaidzik VI, et al. Monitoring of minimal residual disease in NPM1-mutated acute myeloid leukemia: a study from the German-Austrian acute myeloid leukemia study group. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2011;29(19):2709-16.

62. Hubmann M, Kohnke T, Hoster E, Schneider S, Dufour A, Zellmeier E, et al. Molecular response assessment by quantitative real-time polymerase chain reaction after induction therapy in NPM1-mutated patients identifies those at high risk of relapse. Haematologica. 2014;99(8):1317-25.

63. Yin JA, O'Brien MA, Hills RK, Daly SB, Wheatley K, Burnett AK. Minimal residual disease monitoring by quantitative RT-PCR in core binding factor AML allows risk stratification and predicts relapse: results of the United Kingdom MRC AML-15 trial. Blood. 2012;120(14):2826-35.

64. Terwijn M, van Putten WL, Kelder A, van der Velden VH, Brooimans RA, Pabst T, et al. High Prognostic Impact of Flow Cytometric Minimal Residual Disease Detection in Acute Myeloid Leukemia: Data From the HOVON/SAKK AML 42A Study. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2013.

65. Tierens A, Bjorklund E, Siitonen S, Marquart HV, Wulff-Juergensen G, Pelliniemi TT, et al. Residual disease detected by flow cytometry is an independent predictor of survival in childhood acute myeloid leukaemia; results of the NOPHO-AML 2004 study. British journal of haematology. 2016;174(4):600-9.

66. Dombret H, Seymour JF, Butrym A, Wierzbowska A, Selleslag D, Jang JH, et al. International phase 3 study of azacitidine vs conventional care regimens in older patients with newly diagnosed AML with >30% blasts. Blood. 2015;126(3):291-9.

67. Castaigne S, Pautas C, Terré C, Raffoux E, Bordessoule D, Bastie J-N, et al. Effect of gemtuzumab ozogamicin on survival of adult patients with de-novo acute myeloid leukaemia (ALFA-0701): a randomised, open-label, phase 3 study. The Lancet. 2012;379(9825):1508-16.

68. Holowiecki J, Grosicki S, Giebel S, Robak T, Kyrcz-Krzemien S, Kuliczkowski K, et al. Cladribine, but not fludarabine, added to daunorubicin and cytarabine during induction prolongs survival of patients with acute myeloid leukemia: a multicenter, randomized phase III study. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2012;30(20):2441-8.

69. Moore JO, George SL, Dodge RK, Amrein PC, Powell BL, Kolitz JE, et al. Sequential multiagent chemotherapy is not superior to high-dose cytarabine alone as postremission intensification therapy for acute myeloid leukemia in adults under 60 years of age: Cancer and Leukemia Group B Study 9222. Blood. 2005;105(9):3420-7.

70. Juliusson G, Hoglund M, Karlsson K, Lofgren C, Mollgard L, Paul C, et al. Increased remissions from one course for intermediate-dose cytosine arabinoside and idarubicin in elderly acute myeloid leukaemia when combined with cladribine. A randomized population-based phase II study. British journal of haematology. 2003;123(5):810-8.

71. Smith GA, Damon LE, Rugo HS, Ries CA, Linker CA. High-dose cytarabine dose modification reduces the incidence of neurotoxicity in patients with renal insufficiency. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 1997;15(2):833-9.

72. Buchner T, Hiddemann W, Wormann B, Loffler H, Gassmann W, Haferlach T, et al. Double induction strategy for acute myeloid leukemia: the effect of high-dose cytarabine with mitoxantrone instead of standard-dose cytarabine with daunorubicin and 6-thioguanine: a randomized trial by the German AML Cooperative Group. Blood. 1999;93(12):4116-24.

73. Nachar VR, Perissinotti AJ, Scappaticci GB, Bixby DL, Marini BL. Predictors for requiring re-induction chemotherapy in acute myeloid leukemia patients with residual disease on day 14 bone marrow assessment. Leukemia research. 2017;63:56-61.

74. Terry CM, Shallis RM, Estey E, Lim SH. Day 14 bone marrow examination in the management of acute myeloid leukemia. Am J Hematol. 2017;92(10):1079-84.

75. Wahlin A. Amsacrine, cytarabine and etoposide in the treatment of bad prognosis acute myeloid leukemia. Medical oncology and tumor pharmacotherapy. 1989;6(3):199-205.

76. Pastore D, Specchia G, Carluccio P, Liso A, Mestice A, Rizzi R, et al. FLAG-IDA in the treatment of refractory/relapsed acute myeloid leukemia: single-center experience. Annals of hematology. 2003;82(4):231-5.

77. Hiddemann W, Kreutzmann H, Straif K, Ludwig WD, Mertelsmann R, Donhuijsen-Ant R, et al. High-dose cytosine arabinoside and mitoxantrone: a highly effective regimen in refractory acute myeloid leukemia. Blood. 1987;69(3):744-9.

78. Tallman MS, Brenner B, Serna Jde L, Dombret H, Falanga A, Kwaan HC, et al. Meeting report. Acute promyelocytic leukemia-associated coagulopathy, 21 January 2004, London, United Kingdom. Leukemia research. 2005;29(3):347-51.

79. Lo-Coco F, Avvisati G, Vignetti M, Thiede C, Orlando SM, Iacobelli S, et al. Retinoic acid and arsenic trioxide for acute promyelocytic leukemia. The New England journal of medicine. 2013;369(2):111-21.

80. Lo-Coco F, Di Donato L, Gimema, Schlenk RF, German-Austrian Acute Myeloid Leukemia Study G, Study Alliance L. Targeted Therapy Alone for Acute Promyelocytic Leukemia. The New England journal of medicine. 2016;374(12):1197-8.

81. Burnett AK, Russell NH, Hills RK, Bowen D, Kell J, Knapper S, et al. Arsenic trioxide and all-trans retinoic acid treatment for acute promyelocytic leukaemia in all risk groups (AML17): results of a randomised, controlled, phase 3 trial. The lancet oncology. 2015;16(13):1295-305.

82. Iland HJ, Bradstock K, Supple SG, Catalano A, Collins M, Hertzberg M, et al. All-trans-retinoic acid, idarubicin, and IV arsenic trioxide as initial therapy in acute promyelocytic leukemia (APML4). Blood. 2012;120(8):1570-80; quiz 752.

83. Sanz MA, Montesinos P. How we prevent and treat differentiation syndrome in patients with acute promyelocytic leukemia. Blood. 2014;123(18):2777-82.

84. Smith MB, Griffiths EA, Thompson JE, Wang ES, Wetzler M, Freyer CW. High pseudotumor cerebri incidence in tretinoin and arsenic treated acute promyelocytic leukemia and the role of topiramate after acetazolamide failure. Leuk Res Rep. 2014;3(2):62-6.

85. Coombs CC, DeAngelis LM, Feusner JH, Rowe JM, Tallman MS. Pseudotumor Cerebri in Acute Promyelocytic Leukemia Patients on Intergroup Protocol 0129: Clinical Description and Recommendations for New Diagnostic Criteria. Clin Lymphoma Myeloma Leuk. 2016;16(3):146-51.

86. Roboz GJ, Ritchie EK, Carlin RF, Samuel M, Gale L, Provenzano-Gober JL, et al. Prevalence, management, and clinical consequences of QT interval prolongation during treatment with arsenic trioxide. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2014;32(33):3723-8.

87. Lengfelder E, Lo-Coco F, Ades L, Montesinos P, Grimwade D, Kishore B, et al. Arsenic trioxide-based therapy of relapsed acute promyelocytic leukemia: registry results from the European LeukemiaNet. Leukemia. 2015;29(5):1084-91.

88. Morra E, Lazzarino M, Alessandrino EP, Inverardi D, Regazzi Bonora M, Pagnucco G, et al. Central nervous system (CNS) leukemia: the role of high dose cytarabine (HDAra-C). Bone marrow transplantation. 1989;4 Suppl 1:101-3.

89. Pinkel D, Woo S. Prevention and treatment of meningeal leukemia in children. Blood. 1994;84(2):355-66.

90. Zheng C, Liu X, Zhu W, Cai X, Wu J, Sun Z. Tailored central nervous system-directed treatment strategy for isolated CNS recurrence of adult acute myeloid leukemia. Hematology. 2014;19(4):208-12.

91. Tsimberidou AM, Kantarjian HM, Wen S, Keating MJ, O'Brien S, Brandt M, et al. Myeloid sarcoma is associated with superior event-free survival and overall survival compared with acute myeloid leukemia. Cancer. 2008;113(6):1370-8.

92. Almond LM, Charalampakis M, Ford SJ, Gourevitch D, Desai A. Myeloid Sarcoma: Presentation, Diagnosis, and Treatment. Clin Lymphoma Myeloma Leuk. 2017;17(5):263-7.

93. Greenwood MJ, Seftel MD, Richardson C, Barbaric D, Barnett MJ, Bruyere H, et al. Leukocyte count as a predictor of death during remission induction in acute myeloid leukemia. Leuk Lymphoma. 2006;47(7):1245-52.

94. Powles R, Sirohi B, Kulkarni S. The effective prevention and management of common complications of induction chemotherapy in haematological malignancy. Pinketon R, Rohatiner A, Miles A, editors: Aesculapius Medical Press; 2003.

 

95. Oberoi S, Lehrnbecher T, Phillips B, Hitzler J, Ethier MC, Beyene J, et al. Leukapheresis and low-dose chemotherapy do not reduce early mortality in acute myeloid leukemia hyperleukocytosis: a systematic review and meta-analysis. Leukemia research. 2014;38(4):460-8.

 

96. Dutcher JP, Schiffer CA, Wiernik PH. Hyperleukocytosis in adult acute nonlymphocytic leukemia: impact on remission rate and duration, and survival. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 1987;5(9):1364-72.

97. Nowacki P, Zdziarska B, Fryze C, Urasinski I. Co-existence of thrombocytopenia and hyperleukocytosis ('critical period') as a risk factor of haemorrhage into the central nervous system in patients with acute leukaemias. Haematologia (Budap). 2002;31(4):347-55.

98. Cairo MS, Bishop M. Tumour lysis syndrome: new therapeutic strategies and classification. British journal of haematology. 2004;127(1):3-11.

99. Jones GL, Will A, Jackson GH, Webb NJ, Rule S. Guidelines for the management of tumour lysis syndrome in adults and children with haematological malignancies on behalf of the British Committee for Standards in Haematology. British journal of haematology. 2015;169(5):661-71.

100. Goldman SC, Holcenberg JS, Finklestein JZ, Hutchinson R, Kreissman S, Johnson FL, et al. A randomized comparison between rasburicase and allopurinol in children with lymphoma or leukemia at high risk for tumor lysis. Blood. 2001;97(10):2998-3003.

101. Lopez-Olivo MA, Pratt G, Palla SL, Salahudeen A. Rasburicase in Tumor Lysis Syndrome of the Adult: A Systematic Review and Meta-analysis. American journal of kidney diseases : the official journal of the National Kidney Foundation. 2013;62(3):481-92.

102. Vadhan-Raj S, Fayad LE, Fanale MA, Pro B, Rodriguez A, Hagemeister FB, et al. A randomized trial of a single-dose rasburicase versus five-daily doses in patients at risk for tumor lysis syndrome. Annals of oncology : official journal of the European Society for Medical Oncology / ESMO. 2012;23(6):1640-5.

103. Cairo MS, Coiffier B, Reiter A, Younes A, Panel TLSE. Recommendations for the evaluation of risk and prophylaxis of tumour lysis syndrome (TLS) in adults and children with malignant diseases: an expert TLS panel consensus. British journal of haematology. 2010;149(4):578-86.

104. Brenner B, Avivi I, Lishner M. Haematological cancers in pregnancy. Lancet. 2012;379(9815):580-7.

105. Milojkovic D, Apperley JF. How I treat leukemia during pregnancy. Blood. 2014;123(7):974-84.

106. Verma V, Giri S, Manandhar S, Pathak R, Bhatt VR. Acute promyelocytic leukemia during pregnancy: a systematic analysis of outcome. Leuk Lymphoma. 2016;57(3):616-22.

107. How I diagnose and manage individuals at risk for inherited myeloid malignancies. Blood. 2016;128(14):1800-13.

108. DiNardo CD, Bannon SA, Routbort M, Franklin A, Mork M, Armanios M, et al. Evaluation of Patients and Families With Concern for Predispositions to Hematologic Malignancies Within the Hereditary Hematologic Malignancy Clinic (HHMC). Clin Lymphoma Myeloma Leuk. 2016;16(7):417-28.e2.

109. Keel SB, Scott A, Sanchez-Bonilla M, Ho PA, Gulsuner S, Pritchard CC, et al. Genetic features of myelodysplastic syndrome and aplastic anemia in pediatric and young adult patients. Haematologica. 2016;101(11):1343-50.

110. Burnett AK, Wheatley K, Goldstone AH, Stevens RF, Hann IM, Rees JH, et al. The value of allogeneic bone marrow transplant in patients with acute myeloid leukaemia at differing risk of relapse: results of the UK MRC AML 10 trial. British journal of haematology. 2002;118(2):385-400.

111. Cassileth PA, Harrington DP, Appelbaum FR, Lazarus HM, Rowe JM, Paietta E, et al. Chemotherapy compared with autologous or allogeneic bone marrow transplantation in the management of acute myeloid leukemia in first remission. The New England journal of medicine. 1998;339(23):1649-56.

112. Zittoun RA, Mandelli F, Willemze R, de Witte T, Labar B, Resegotti L, et al. Autologous or allogeneic bone marrow transplantation compared with intensive chemotherapy in acute myelogenous leukemia. European Organization for Research and Treatment of Cancer (EORTC) and the Gruppo Italiano Malattie Ematologiche Maligne dell'Adulto (GIMEMA) Leukemia Cooperative Groups. The New England journal of medicine. 1995;332(4):217-23.

113. Cornelissen JJ, van Putten WL, Verdonck LF, Theobald M, Jacky E, Daenen SM, et al. Results of a HOVON/SAKK donor versus no-donor analysis of myeloablative HLA-identical sibling stem cell transplantation in first remission acute myeloid leukemia in young and middle-aged adults: benefits for whom? Blood. 2007;109(9):3658-66.

114. Versluis J, Kalin, B., Zeijlemarker, W., Passweg, J., Graux, C., Mant, MG, et al. Graft-Versus-Leukemia Effect of Allogeneic Stem-Cell Transplantation and Minimal Residual Disease in Patients With Acute Myeloid Leukemia in First Complete Remission JCO Precision Oncology; 2017. p. 1-13.

115. Anasetti C, Logan BR, Confer DL, Blood, Marrow Transplant Clinical Trials N. Peripheral-blood versus bone marrow stem cells. The New England journal of medicine. 2013;368(3):288.

116. Mohty M, Kuentz M, Michallet M, Bourhis JH, Milpied N, Sutton L, et al. Chronic graft-versus-host disease after allogeneic blood stem cell transplantation: long-term results of a randomized study. Blood. 2002;100(9):3128-34.

117. Slavin S, Nagler A, Naparstek E, Kapelushnik Y, Aker M, Cividalli G, et al. Nonmyeloablative stem cell transplantation and cell therapy as an alternative to conventional bone marrow transplantation with lethal cytoreduction for the treatment of malignant and nonmalignant hematologic diseases. Blood. 1998;91(3):756-63.

118. Ringden O, Labopin M, Ehninger G, Niederwieser D, Olsson R, Basara N, et al. Reduced intensity conditioning compared with myeloablative conditioning using unrelated donor transplants in patients with acute myeloid leukemia. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2009;27(27):4570-7.

119. Blaise DP, Michel Boiron J, Faucher C, Mohty M, Bay JO, Bardoux VJ, et al. Reduced intensity conditioning prior to allogeneic stem cell transplantation for patients with acute myeloblastic leukemia as a first-line treatment. Cancer. 2005;104(9):1931-8.

120. Scott BL, Pasquini MC, Logan BR, Wu J, Devine SM, Porter DL, et al. Myeloablative Versus Reduced-Intensity Hematopoietic Cell Transplantation for Acute Myeloid Leukemia and Myelodysplastic Syndromes. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2017;35(11):1154-61.

121. Bokhari SW, Watson L, Nagra S, Cook M, Byrne JL, Craddock C, et al. Role of HCT-comorbidity index, age and disease status at transplantation in predicting survival and non-relapse mortality in patients with myelodysplasia and leukemia undergoing reduced-intensity-conditioning hemopoeitic progenitor cell transplantation. Bone marrow transplantation. 2012;47(4):528-34.

122. Lee SJ, Klein J, Haagenson M, Baxter-Lowe LA, Confer DL, Eapen M, et al. High-resolution donor-recipient HLA matching contributes to the success of unrelated donor marrow transplantation. Blood. 2007;110(13):4576-83.

123. Ivey A, Hills RK, Simpson MA, Jovanovic JV, Gilkes A, Grech A, et al. Assessment of Minimal Residual Disease in Standard-Risk AML. The New England journal of medicine. 2016;374(5):422-33.

124. Craddock C, Tauro S, Moss P, Grimwade D. Biology and management of relapsed acute myeloid leukaemia. British journal of haematology. 2005;129(1):18-34.

125. Craddock C, Labopin M, Pillai S, Finke J, Bunjes D, Greinix H, et al. Factors predicting outcome after unrelated donor stem cell transplantation in primary refractory acute myeloid leukaemia. Leukemia. 2011;25(5):808-13.

126. Duval M, Klein JP, He W, Cahn JY, Cairo M, Camitta BM, et al. Hematopoietic stem-cell transplantation for acute leukemia in relapse or primary induction failure. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2010;28(23):3730-8.

127. Schmid C, Schleuning M, Hentrich M, Markl GE, Gerbitz A, Tischer J, et al. High antileukemic efficacy of an intermediate intensity conditioning regimen for allogeneic stem cell transplantation in patients with high-risk acute myeloid leukemia in first complete remission. Bone marrow transplantation. 2008;41(8):721-7.

128. Schmid C, Schleuning M, Ledderose G, Tischer J, Kolb HJ. Sequential regimen of chemotherapy, reduced-intensity conditioning for allogeneic stem-cell transplantation, and prophylactic donor lymphocyte transfusion in high-risk acute myeloid leukemia and myelodysplastic syndrome. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2005;23(24):5675-87.

129. Schmid C, Schleuning M, Tischer J, Holler E, Haude KH, Braess J, et al. Early allo-SCT for AML with a complex aberrant karyotype--results from a prospective pilot study. Bone marrow transplantation. 2012;47(1):46-53.

130. Schroeder T, Czibere A, Platzbecker U, Bug G, Uharek L, Luft T, et al. Azacitidine and donor lymphocyte infusions as first salvage therapy for relapse of AML or MDS after allogeneic stem cell transplantation. Leukemia. 2013;27(6):1229-35.

131. Pfirrmann M, Ehninger G, Thiede C, Bornhauser M, Kramer M, Rollig C, et al. Prediction of post-remission survival in acute myeloid leukaemia: a post-hoc analysis of the AML96 trial. The lancet oncology. 2012;13(2):207-14.

132. Ganzel C, Rowe JM. Revisiting autologous transplantation in acute myeloid leukemia. Curr Opin Hematol. 2018;25(2):95-102.

133. Rashidi A, Walter RB, Tallman MS, Appelbaum FR, DiPersio JF. Maintenance therapy in acute myeloid leukemia: an evidence-based review of randomized trials. Blood. 2016;128(6):763-73.

134. Brune M, Castaigne S, Catalano J, Gehlsen K, Ho AD, Hofmann WK, et al. Improved leukemia-free survival after postconsolidation immunotherapy with histamine dihydrochloride and interleukin-2 in acute myeloid leukemia: results of a randomized phase 3 trial. Blood. 2006;108(1):88-96.

135. Brune M, Romero AI, Hellstrand K. Histamine dihydrochloride and interleukin-2 in acute myeloid leukemia--background and results. Inflammation research : official journal of the European Histamine Research Society  [et al]. 2009;58 Suppl 1:4-8.

136. Thoren FB, Romero AI, Brune M, Hellstrand K. Histamine dihydrochloride and low-dose interleukin-2 as post-consolidation immunotherapy in acute myeloid leukemia. Expert opinion on biological therapy. 2009;9(9):1217-23.

137. Martner A, Rydstrom A, Riise RE, Aurelius J, Brune M, Foa R, et al. NK cell expression of natural cytotoxicity receptors may determine relapse risk in older AML patients undergoing immunotherapy for remission maintenance. Oncotarget. 2015;6(40):42569-74.

138. Martner A, Wiktorin HG, Lenox B, Ewald Sander F, Aydin E, Aurelius J, et al. Histamine promotes the development of monocyte-derived dendritic cells and reduces tumor growth by targeting the myeloid NADPH oxidase. Journal of immunology (Baltimore, Md : 1950). 2015;194(10):5014-21.

139. Huls G, Chity, D., Havelange, V., Jongen-Lavrencic, M., van de Loosdrecht, A.,Biemond, BM, et al. Randomized Maintenance Therapy with Azacitidine (Vidaza) in Older Patients (≥ 60 years of age) with Acute Myeloid Leukemia (AML) and Refractory Anemia with Excess of Blasts (RAEB, RAEB-t). Results of the HOVON97 Phase III Randomized Multicentre Study (EudraCT 2008-001290-15).  ASH Annual Meeting Abstracts: Blood; 2017. p. 463-.

140. Heil G, Hoelzer D, Sanz MA, Lechner K, Liu Yin JA, Papa G, et al. A randomized, double-blind, placebo-controlled, phase III study of filgrastim in remission induction and consolidation therapy for adults with de novo acute myeloid leukemia. The International Acute Myeloid Leukemia Study Group. Blood. 1997;90(12):4710-8.

141. Ratko TA, Cummings JP, Oberman HA, Crookston KP, DeChristopher PJ, Eastlund DT, et al. Evidence-based recommendations for the use of WBC-reduced cellular blood components. Transfusion. 2001;41(10):1310-9.

142. Treleaven J, Gennery A, Marsh J, Norfolk D, Page L, Parker A, et al. Guidelines on the use of irradiated blood components prepared by the British Committee for Standards in Haematology blood transfusion task force. British journal of haematology. 2011;152(1):35-51.

143. Wandt H, Schaefer-Eckart K, Wendelin K, Pilz B, Wilhelm M, Thalheimer M, et al. Therapeutic platelet transfusion versus routine prophylactic transfusion in patients with haematological malignancies: an open-label, multicentre, randomised study. Lancet. 2012;380(9850):1309-16.

144. Stanworth SJ, Estcourt LJ, Powter G, Kahan BC, Dyer C, Choo L, et al. A no-prophylaxis platelet-transfusion strategy for hematologic cancers. The New England journal of medicine. 2013;368(19):1771-80.

145. Kelsey P. Guidelines for the use of platlet transfusions. British Committee for Standars in Haematology, Blood Transfusion Task Force. British journal of haematology. 2003;122:10-23.

146. Harris AL. Leukostasis associated with blood transfusion in acute myeloid leukaemia. British medical journal. 1978;1(6121):1169-71.

147. Cherif H, Axdorph U, Kalin M, Bjorkholm M. Clinical experience of granulocyte transfusion in the management of neutropenic patients with haematological malignancies and severe infection. Scandinavian journal of infectious diseases. 2013;45(2):112-6.

148. Price TH, Boeckh M, Harrison RW, McCullough J, Ness PM, Strauss RG, et al. Efficacy of transfusion with granulocytes from G-CSF/dexamethasone-treated donors in neutropenic patients with infection. Blood. 2015;126(18):2153-61.

149. Berlin G, Cherif, H., Knutsson, F., Mattsson, J. Granulocyttransfusion bör övervägas vid neutropeni och allvarlig infektion. Läkartidningen. 2018;115:115 (EXUU).

150. Gafter-Gvili A, Fraser A, Paul M, Leibovici L. Meta-analysis: antibiotic prophylaxis reduces mortality in neutropenic patients. Annals of internal medicine. 2005;142(12 Pt 1):979-95.

151. Moller T, Nielsen OJ, Welinder P, Dunweber A, Hjerming M, Moser C, et al. Safe and feasible outpatient treatment following induction and consolidation chemotherapy for patients with acute leukaemia. European journal of haematology. 2010;84(4):316-22.

152. Lonnqvist B, Palmblad J, Ljungman P, Grimfors G, Jarnmark M, Lerner R, et al. Oral acyclovir as prophylaxis for bacterial infections during induction therapy for acute leukaemia in adults. The Leukemia Group of Middle Sweden. Support Care Cancer. 1993;1(3):139-44.

153. Cornely OA, Maertens J, Winston DJ, Perfect J, Ullmann AJ, Walsh TJ, et al. Posaconazole vs. fluconazole or itraconazole prophylaxis in patients with neutropenia. The New England journal of medicine. 2007;356(4):348-59.

154. MPA, Swedish. Behandling och profylax av invasiva svampinfektioner. Läkemedelsverkets Workshop. 2011.

155. Grau S, de la Camara R, Sabater FJ, Jarque I, Carreras E, Casado MA, et al. Cost-effectiveness of posaconazole versus fluconazole or itraconazole in the prevention of invasive fungal infections among high-risk neutropenic patients in Spain. BMC infectious diseases. 2012;12:83.

156. Winston DJ, Chandrasekar PH, Lazarus HM, Goodman JL, Silber JL, Horowitz H, et al. Fluconazole prophylaxis of fungal infections in patients with acute leukemia. Results of a randomized placebo-controlled, double-blind, multicenter trial. Annals of internal medicine. 1993;118(7):495-503.

157. Bow EJ, Laverdiere M, Lussier N, Rotstein C, Cheang MS, Ioannou S. Antifungal prophylaxis for severely neutropenic chemotherapy recipients: a meta analysis of randomized-controlled clinical trials. Cancer. 2002;94(12):3230-46.

158. Maertens J, Frére P, Lass-Flörl C, Heinz W, Cornely OA. Primary antifungal prophylaxis in leukaemia patients. European Journal of Cancer (Suppl). 2007;5(2):43-8.

159. Giebel S, Thomas X, Hallbook H, Geissler K, Boiron JM, Huguet F, et al. The prophylactic use of granulocyte-colony stimulating factor during remission induction is associated with increased leukaemia-free survival of adults with acute lymphoblastic leukaemia: a joint analysis of five randomised trials on behalf of the EWALL. European journal of cancer. 2012;48(3):360-7.

160. MPA S. Granulocyte Colony-Stimulating Factor (G-CSF), Granulocyte-Macrophage Stimulating Factor (GM-CSF) and Erythropoietin in Haematology and Oncology (Workshop).  workshop2001.

161. Agarwal A, Ranganathan P, Kattal N, Pasqualotto F, Hallak J, Khayal S, et al. Fertility after cancer: a prospective review of assisted reproductive outcome with banked semen specimens. Fertil Steril. 2004;81(2):342-8.

162. Hovatta O. Cryopreservation and culture of human ovarian cortical tissue containing early follicles. Eur J Obstet Gynecol Reprod Biol. 2004;113 Suppl 1:S50-4.

163. Loren AW, Mangu PB, Beck LN, Brennan L, Magdalinski AJ, Partridge AH, et al. Fertility preservation for patients with cancer: American Society of Clinical Oncology clinical practice guideline update. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2013;31(19):2500-10.

164. Wallace WH. Oncofertility and preservation of reproductive capacity in children and young adults. Cancer. 2011;117(10 Suppl):2301-10.

165. Rosendahl M, Andersen MT, Ralfkiaer E, Kjeldsen L, Andersen MK, Andersen CY. Evidence of residual disease in cryopreserved ovarian cortex from female patients with leukemia. Fertil Steril. 2010;94(6):2186-90.

166. Armuand GM, Rodriguez-Wallberg KA, Wettergren L, Ahlgren J, Enblad G, Hoglund M, et al. Sex differences in fertility-related information received by young adult cancer survivors. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2012;30(17):2147-53.

167. Rashidi A, Weisdorf DJ, Bejanyan N. Treatment of relapsed/refractory acute myeloid leukaemia in adults. British journal of haematology. 2018;181(1):27-37.

168. Leopold LH, Willemze R. The treatment of acute myeloid leukemia in first relapse: a comprehensive review of the literature. Leuk Lymphoma. 2002;43(9):1715-27.

169. Breems DA, Van Putten WL, Huijgens PC, Ossenkoppele GJ, Verhoef GE, Verdonck LF, et al. Prognostic index for adult patients with acute myeloid leukemia in first relapse. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2005;23(9):1969-78.

170. Nationellt vårdprogram för palliativ vård: Regionalt cancercentrum i Samverkan; [updated 2017]

171. Funke I, Wiesneth M, Platow S, Kubanek B. Palliative cytoreduction in refractory acute leukemia: a retrospective study of 57 adult patients. Annals of hematology. 2000;79(3):132-7.

172. Nationellt vårdprogram för cancerrehabilitering: Regionalt cancercentrum i Samverkan;  [updated 2017].

173. Korol EE, Wang S, Johnston K, Ravandi-Kashani F, Levis M, van Nooten F. Health-Related Quality of Life of Patients with Acute Myeloid Leukemia: A Systematic Literature Review. Oncol Ther. 2017;5(1):1-16.

174. Leunis A, Redekop WK, Uyl-de Groot CA, Lowenberg B. Impaired health-related quality of life in acute myeloid leukemia survivors: a single-center study. European journal of haematology. 2014;93(3):198-206.

175. Ahrnstedt A, Sörensen K. Vårdhandboken: Inera AB; 2012.

176. Leak Bryant A, Lee Walton A, Shaw-Kokot J, Mayer DK, Reeve BB. Patient-reported symptoms and quality of life in adults with acute leukemia: a systematic review. Oncol Nurs Forum. 2015;42(2):E91-E101.

177. Alibhai SM, O'Neill S, Fisher-Schlombs K, Breunis H, Brandwein JM, Timilshina N, et al. A clinical trial of supervised exercise for adult inpatients with acute myeloid leukemia (AML) undergoing induction chemotherapy. Leukemia research. 2012;36(10):1255-61.

178. Chang PH, Lai YH, Shun SC, Lin LY, Chen ML, Yang Y, et al. Effects of a walking intervention on fatigue-related experiences of hospitalized acute myelogenous leukemia patients undergoing chemotherapy: a randomized controlled trial. Journal of pain and symptom management. 2008;35(5):524-34.

179. Hellberg E, Nissander, N. Fysioterapeutiskt vårdprogram för patienter som genomgår cytostatikabehandling på grund av hematologisk malignitet 2017 [cited 5]. Available from: https://www.fysioterapeuterna.se.

180. Bozzetti F, Arends J, Lundholm K, Micklewright A, Zurcher G, Muscaritoli M, et al. ESPEN Guidelines on Parenteral Nutrition: non-surgical oncology. Clinical nutrition. 2009;28(4):445-54.

181. van Dalen EC, Mank A, Leclercq E, Mulder RL, Davies M, Kersten MJ, et al. Low bacterial diet versus control diet to prevent infection in cancer patients treated with chemotherapy causing episodes of neutropenia. The Cochrane database of systematic reviews. 2016;4:Cd006247.

182. Roila F, Molassiotis A, Herrstedt J, Aapro M, Gralla RJ, Bruera E, et al. 2016 MASCC and ESMO guideline update for the prevention of chemotherapy- and radiotherapy-induced nausea and vomiting and of nausea and vomiting in advanced cancer patients. Annals of oncology : official journal of the European Society for Medical Oncology / ESMO. 2016;27(suppl 5):v119-v33.

183. Elad S, Raber-Durlacher JE, Brennan MT, Saunders DP, Mank AP, Zadik Y, et al. Basic oral care for hematology-oncology patients and hematopoietic stem cell transplantation recipients: a position paper from the joint task force of the Multinational Association of Supportive Care in Cancer/International Society of Oral Oncology (MASCC/ISOO) and the European Society for Blood and Marrow Transplantation (EBMT). Support Care Cancer. 2015;23(1):223-36.

184. Keefe DM, Schubert MM, Elting LS, Sonis ST, Epstein JB, Raber-Durlacher JE, et al. Updated clinical practice guidelines for the prevention and treatment of mucositis. Cancer. 2007;109(5):820-31.

185. Sanchez Varela V, Zhou ES, Bober SL. Management of sexual problems in cancer patients and survivors. Curr Probl Cancer. 2013;37(6):319-52.

186. Olsson C, Sandin-Bojo AK, Bjuresater K, Larsson M. Patients treated for hematologic malignancies: affected sexuality and health-related quality of life. Cancer nursing. 2015;38(2):99-110.

187. Hammarskjold F, Wallen G, Malmvall BE. Central venous catheter infections at a county hospital in Sweden: a prospective analysis of colonization, incidence of infection and risk factors. Acta anaesthesiologica Scandinavica. 2006;50(4):451-60.

188. Johansson E. Cental Venous Access Devices in patients with hematological malignancies: Care, Complications and treatment 2003.

189. Acosta S, Frykholm P, Hammarskjöld F, Larsson A, Lindgren S, Lindwall R, et al. SFAI:s riktlinjer för centrala venkatetrar 2011. Available from: http://www.sfai.se/riktlinjer/cvk-0.

190. Guidelines for the Prevention of Intravascular Catheter-Related Infections: (CDC) Centers of Disease Control and Prevention:s hemsida: ; 2017. 

191. Lee SH, Erber WN, Porwit A, Tomonaga M, Peterson LC. ICSH guidelines for the standardization of bone marrow specimens and reports. Int J Lab Hematol. 2008;30(5):349-64.

192. Burnett AK, Russell NH, Hills RK, Kell J, Cavenagh J, Kjeldsen L, et al. A randomized comparison of daunorubicin 90 mg/m2 vs 60 mg/m2 in AML induction: results from the UK NCRI AML17 trial in 1206 patients. Blood. 2015;125(25):3878-85.

193. Teuffel O, Leibundgut K, Lehrnbecher T, Alonzo TA, Beyene J, Sung L. Anthracyclines during induction therapy in acute myeloid leukaemia: a systematic review and meta-analysis. British journal of haematology. 2013;161(2):192-203.

194. Wang J, Yang YG, Zhou M, Xu JY, Zhang QG, Zhou RF, et al. Meta-analysis of randomised clinical trials comparing idarubicin + cytarabine with daunorubicin + cytarabine as the induction chemotherapy in patients with newly diagnosed acute myeloid leukaemia. PloS one. 2013;8(4):e60699.

195. van Dalen EC, van der Pal HJ, Kremer LC. Different dosage schedules for reducing cardiotoxicity in people with cancer receiving anthracycline chemotherapy. The Cochrane database of systematic reviews. 2016;3:Cd005008.

196. Kane RC, McGuinn WD, Jr., Dagher R, Justice R, Pazdur R. Dexrazoxane (Totect): FDA review and approval for the treatment of accidental extravasation following intravenous anthracycline chemotherapy. The oncologist. 2008;13(4):445-50.

197. Mouridsen HT, Langer SW, Buter J, Eidtmann H, Rosti G, de Wit M, et al. Treatment of anthracycline extravasation with Savene (dexrazoxane): results from two prospective clinical multicentre studies. Annals of oncology : official journal of the European Society for Medical Oncology / ESMO. 2007;18(3):546-50.

198. Kern W, Estey EH. High-dose cytosine arabinoside in the treatment of acute myeloid leukemia: Review of three randomized trials. Cancer. 2006;107(1):116-24.

199. Kintzel PE, Dorr RT. Anticancer drug renal toxicity and elimination: dosing guidelines for altered renal function. Cancer treatment reviews. 1995;21(1):33-64.

200. Farag SS, Ruppert AS, Mrozek K, Mayer RJ, Stone RM, Carroll AJ, et al. Outcome of induction and postremission therapy in younger adults with acute myeloid leukemia with normal karyotype: a cancer and leukemia group B study. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2005;23(3):482-93.

201. Russo D, Malagola M, Martinelli G, Damiani D, Isidori A, De Vivo A, et al. Efficacy and Toxicity of FLAI vs ICE for Induction Treatment of Newly Diagnosed AML Patients, Younger Than 60 Years. Blood. 2004;104(11 supp 1):250a; abstract #878.

202. Robak T. Purine nucleoside analogues in the treatment of myleoid leukemias. Leuk Lymphoma. 2003;44(3):391-409.

203. Faderl S, Gandhi V, O'Brien S, Bonate P, Cortes J, Estey E, et al. Results of a phase 1-2 study of clofarabine in combination with cytarabine (ara-C) in relapsed and refractory acute leukemias. Blood. 2005;105(3):940-7.

204. Fenaux P, Mufti GJ, Hellstrom-Lindberg E, Santini V, Gattermann N, Germing U, et al. Azacitidine prolongs overall survival compared with conventional care regimens in elderly patients with low bone marrow blast count acute myeloid leukemia. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2010;28(4):562-9.

205. Kantarjian HM, Thomas XG, Dmoszynska A, Wierzbowska A, Mazur G, Mayer J, et al. Multicenter, randomized, open-label, phase III trial of decitabine versus patient choice, with physician advice, of either supportive care or low-dose cytarabine for the treatment of older patients with newly diagnosed acute myeloid leukemia. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2012;30(21):2670-7.

206. Godwin CD, Gale RP, Walter RB. Gemtuzumab ozogamicin in acute myeloid leukemia. Leukemia. 2017;31(9):1855-68.

207. Hills RK, Castaigne S, Appelbaum FR, Delaunay J, Petersdorf S, Othus M, et al. Addition of gemtuzumab ozogamicin to induction chemotherapy in adult patients with acute myeloid leukaemia: a meta-analysis of individual patient data from randomised controlled trials. The lancet oncology. 2014;15(9):986-96.

208. Petersdorf SH, Kopecky KJ, Slovak M, Willman C, Nevill T, Brandwein J, et al. A phase 3 study of gemtuzumab ozogamicin during induction and postconsolidation therapy in younger patients with acute myeloid leukemia. Blood. 2013;121(24):4854-60.

209. Burnett AK, Russell NH, Hills RK, Hunter AE, Kjeldsen L, Yin J, et al. Optimization of chemotherapy for younger patients with acute myeloid leukemia: results of the medical research council AML15 trial. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2013;31(27):3360-8.

210. Burnett AK, Russell NH, Hills RK, Kell J, Freeman S, Kjeldsen L, et al. Addition of gemtuzumab ozogamicin to induction chemotherapy improves survival in older patients with acute myeloid leukemia. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2012;30(32):3924-31.

211. Delaunay J, Pigneux A, Witz F, Vey N, Blanchet O, Lefebvre P, et al. Addition of Gemtuzumab Ozogamycin to Chemotherapy Improves Event-Free Survival but Not Overall Survival of AML Patients with Intermediate Cytogenetics Not Eligible for Allogeneic Transplantation. Results of the GOELAMS AML 2006 IR Study. Abstract  79. Blood. 2011;118(21):37-8.

212. Stone RM, Mandrekar SJ, Sanford BL, Laumann K, Geyer S, Bloomfield CD, et al. Midostaurin plus Chemotherapy for Acute Myeloid Leukemia with a FLT3 Mutation. The New England journal of medicine. 2017;377(5):454-64.

213. Döhner K, Thiede, C., Larson, R.A., Prior, T.W., Marcucci, G., Jones, D. et al. Prognostic Impact of NPM1/FLT3-ITD genotypes from Randomized Patients with Acute Myeloid Leukemia (AML) Treated within the International Ratify Study. Blood. 2017;130(Suppl 1):467.

214. Larson RA, Mandrekar, S. J., Sanford, B. L., Laumann, K., Geyer, S., Bloomfield, C. D., Thiede, C., Prior, T. W. et al. An Analysis of Maintenance Therapy and Post-Midostaurin Outcomes in the International Prospective Randomized, Placebo-Controlled, Double-Blind Trial (CALGB 10603/RATIFY [Alliance]) for Newly Diagnosed Acute Myeloid Leukemia (AML) Patients with FLT3 Mutations. Blood. 2017;130(Suppl 1):145.

215. Rollig C, Serve H, Huttmann A, Noppeney R, Muller-Tidow C, Krug U, et al. Addition of sorafenib versus placebo to standard therapy in patients aged 60 years or younger with newly diagnosed acute myeloid leukaemia (SORAML): a multicentre, phase 2, randomised controlled trial. The lancet oncology. 2015;16(16):1691-9.

216. Rollig C, Serve, H., Huttmann, A., Noppeney, R., Muller-Tidow, C., Krug, U., Baldus, C. D., Brandts, C. H., Kunzmann, V. et al. The Addition of Sorafenib to Standard AML Treatment Results in a Substantial Reduction in Relapse Risk and Improved Survival. Updated Results from Long-Term Follow-up of the Randomized-Controlled Soraml Trial. Blood. 2017;130(Suppl 1):721.

 

217. Lancet JE, Uy GL, Cortes JE, Newell LF, Lin TL, Ritchie EK, et al. CPX-351 (cytarabine and daunorubicin) Liposome for Injection Versus Conventional Cytarabine Plus Daunorubicin in Older Patients With Newly Diagnosed Secondary Acute Myeloid Leukemia. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2018;36(26):2684-92.